PTI Proteostasis Therapeutics Inc.

4.04
+0.05  (+1%)
Previous Close 3.99
Open 4.04
Price To Book 5.25
Market Cap 205266025
Shares 50,808,422
Volume 448,383
Short Ratio
Av. Daily Volume 1,189,820

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 28-day data released December 11, 2017 - showed improvements in FEV1 of 5.2%. Phase 2 28-day data released December 11, 2017 - showed improvements in FEV1 of 5.2%.
PTI-428
Cystic fibrosis
Phase 1 data due 1Q 2019.
PTI-801 + Symdeko: Corrector
Cystic fibrosis
Phase 1 data from fourth cohort are due 1Q 2019.
PTI-801 and PTI-808
Cystic fibrosis
Phase 1 full data due 1Q 2019.
PTI-428 + PTI-801 + PTI-808
Cystic fibrosis
Phase 2 data due 1Q 2019.
PTI-428 + Symdeko
Cystic fibrosis

Latest News

  1. Proteostasis Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  2. Biotech Plays in the News You Should Know
  3. How Much Of Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Do Institutions Own?
  4. Biotech Stocks Set to Pop
  5. 4 Biotech Stocks Making Moves on Wednesday (2/6/19)
  6. Proteostasis Therapeutics Appoints Emmanuel Dulac and Kim Drapkin to Board of Directors
  7. These 4 Biotech Stocks Are Raising Eyebrows
  8. The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial
  9. Proteostasis Therapeutics Provides Clinical Enrollment Update
  10. How Many Insiders Bought Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Shares?
  11. Implied Volatility Surging for Proteostasis Therapeutics (PTI) Stock Options
  12. Waltham's Eloxx aims to reach cystic fibrosis patients that Vertex can't
  13. This Week's Top Tech Earnings and Today's Trending Stocks: PTI & NBEV
  14. Biotech News: Proteostasis Therapeutics (PTI) Stock Soars on Genentech
  15. Proteostasis Therapeutics Rallies On Genentech Licensing Agreement
  16. Proteostasis Therapeutics Announces Global License Agreement with Genentech
  17. Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed
  18. Proteostasis Therapeutics to Participate in Upcoming Investor Conferences
  19. Is the Options Market Predicting a Spike in Proteostasis Therapeutics (PTI) Stock?
  20. Proteostasis Therapeutics (PTI) Reports Q3 Loss, Tops Revenue Estimates